Experimental Therapeutics Program

实验治疗计划

基本信息

批准号：
10477971
负责人：
Hans Hammers
金额：
$ 7.93万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10477971
关键词：
Acidosis Address Adult Antitumor Response Area Autoantibodies Award Back Basic Science Biological Markers Biotechnology Breast Catchment Area Cell Cycle Checkpoint Cells Chemical Modifier Chemicals Clinic Clinical Clinical Research Clinical Trials Clinical Trials Design Communities Community Outreach Comprehensive Cancer Center Correlative Study Custom DNA Repair Development Diagnostic Disease Drug Delivery Systems Education Epigenetic Process Estrogen Receptors Excision Faculty Feedback Funding Future Genomics Goals Hematologic Neoplasms Human Image Immune Immune checkpoint inhibitor Immune response Immunologic Markers Immunologic Surveillance Immunooncology Immunotherapy Infrastructure Investigational Therapies Investments KRAS2 gene Laboratories Lead Leadership Libraries Lung Malignant Childhood Neoplasm Malignant Neoplasms Malignant neoplasm of liver Malignant neoplasm of lung Malignant neoplasm of prostate Medical center Metabolic Metabolism Molecular Monitor NCI Center for Cancer Research Nanotechnology Natural Immunity Natural Products Neoplasm Metastasis Oncology Operative Surgical Procedures Organ Organoids Pathologic Phase Population Sciences Positron-Emission Tomography Pre-Clinical Model Prediction of Response to Therapy Program Sustainability Radiation Oncology Radiation therapy Radiation-Sensitizing Agents Renal carcinoma Research Research Personnel Role Science Specimen Testing Therapeutic Tracer Translating Translational Research Tumor Antigens Work antagonist base biomarker discovery cancer cell cancer diagnosis cancer immunotherapy cancer therapy cancer type clinical development clinical translation clinically relevant combat design drug development early phase clinical trial functional genomics humanized mouse imaging agent imaging capabilities immunogenic improved inhibitor innate immune pathways investigator-initiated trial malignant breast neoplasm member molecular drug target molecular marker mutant nanoparticle neuro-oncology new therapeutic target novel novel strategies precision oncology preclinical development predicting response predictive marker programs recruit response siRNA delivery success synergism targeted cancer therapy therapeutic biomarker therapeutic development therapeutic evaluation therapy outcome therapy resistant translational impact translational research program translational scientist translational study tumor tumor microenvironment tumor progression

项目摘要

The Experimental Therapeutics (ET) Program provides an organized integrated infrastructure that enables both clinical translation of basic and population science research from Simmons Comprehensive Cancer Center (SCCC) research programs and identification of clinically relevant hypotheses for testing by SCCC basic science programs. The four program specific aims focus on therapeutic development and biomarker discovery, where members work collectively to: (1) develop molecular therapeutic sensitizers by focusing on the development of unique tumor-selective agents that enhance existing therapies, (2) target tumor microenvironment with immunotherapy by modulating the role of immune cells in tumor progression, (3) advance imaging and drug delivery by developing novel imaging and nanotechnology delivery platforms to enhance cancer diagnosis and therapy, and (4) exploit cancer vulnerabilities by leveraging synthetic lethalities as new “targeted” therapy for cancer. The ET Program brings together 78 SCCC members from six basic science and 12 clinical departments comprising 44 NCI-funded projects, including two SPOREs and 14 multi-PD/PI awards. In response to evaluative activities and strategic goals to facilitate collaborative translational research, ET recruited new senior clinical researchers; expanded translational studies and investigator-initiated clinical trials (IITs) to include most cancer types and to address the needs of the catchment area; enhanced interactions with SCCC members; integrated radiation oncology faculty into the program; and improved the infrastructure and funding for IITs. ET members participate in and lead multicenter IITs and they collaborate with pharma/biotech, which often leads to investigator-initiated trials and translational studies. Importantly, the funded SPORE programs in kidney and lung cancers and new SPORE applications in prostate and liver cancers are actively supported by ET member expertise. The ET Program has expanded therapeutic pipelines in a majority of adult and pediatric cancers. Highlighted successes include the in-house development and clinical translation of therapeutic strategies for KRAS mutant cancers, HIF2alpha-targeting for kidney cancer, antagonists against mutant estrogen receptors in breast cancers, strategies to activate the STING innate immune pathway, and clinical trials capitalizing on synergy between stereotactic radiation therapy and immune checkpoint inhibitors. Future directions include investment in preclinical models (spheroid/organoid cultures, humanized mice), precision oncology (customized panels, SCCC molecular tumor boards, recruitment of a translational leader in genomic oncology), immuno- oncology (immune profiling; novel PET tracers; systemic and organ-specific autoantibody biomarkers; expansion of the innate immunity program), disease-focused translational research programs (recruitment of leadership in breast, GI, lung, GU, neuro-oncology, hematologic malignancies, and Phase I programs); and expansion of interactions with the Office of Community Outreach, Education & Equity in order to increase clinical trial accruals across our catchment area and among the underserved.

实验疗法（ET）计划提供了有组织的集成基础架构，这两者都可以 Simmons综合癌症中心的基础和人口科学研究的临床翻译（SCCC）研究计划和SCCC基础科学测试的临床相关假设的识别程序。这四个计划的特定目的是关注热开发和生物标志物发现，成员共同致力于：（1）通过关注开发的发展分子治疗传感器可增强现有疗法的独特肿瘤选择剂，（2）靶向肿瘤微环境免疫疗法通过调节免疫细胞在肿瘤进展中的作用，（3）提前成像和药物通过开发新颖的成像和纳米技术输送平台的交付，以增强癌症诊断和治疗，（4）通过利用合成致死性作为新的“有针对性”疗法来利用癌症脆弱性癌症。 ET计划汇集了来自六个基础科学和12个临床部门的78名SCCC成员涵盖了44个NCI资助的项目，包括两个孢子和14个多PD/PI奖。回应评估 ET招募了促进合作转化研究的活动和战略目标，招募了新的高级临床研究人员；扩展的翻译研究和研究者发起的临床试验（IIT）包括大多数癌症类型和满足集水区的需求；增强了与SCCC成员的互动；融合的辐射肿瘤学教师进入该计划；并改善了IIT的基础设施和资金。 ET成员参加并领导多中心IIT，他们与Pharma/Biotech合作，这通常会导致研究者发动的试验和翻译研究。重要的是，肾脏和肺的资助孢子计划 ET成员积极支持前列腺和肝癌中的癌症和新的孢子应用专业知识。 ET计划扩大了大多数成人和儿科取消的治疗管道。突出的成功包括内部开发和治疗策略的临床翻译 KRAS突变癌，HIF2Alpha靶向肾癌，反对突变雌激素受体的拮抗剂乳腺癌，激活刺痛的先天免疫途径的策略以及利用临床试验立体定向放射疗法和免疫检查点抑制剂之间的协同作用。未来的指示包括投资临床前模型（球体/器官培养物，人源化小鼠），精度肿瘤学（定制）面板，SCCC分子肿瘤板，招募基因组肿瘤学领导者），免疫 - 肿瘤学（免疫分析；新型宠物示踪剂；系统性和器官特异性自身抗体生物标志物；扩展关于先天免疫计划），以疾病为中心的翻译研究计划（招募领导力乳房，胃肠道，肺，GU，神经肿瘤学，血液学恶性肿瘤和I期计划）；和扩展与社区外展，教育和公平办公室的互动，以增加临床试验在我们的集水区以及服务欠缺的地区。